Joshua Barton

CDC Center for Disease Control and Prevention COVID-19 coronavirus disease 2019 ILI influenza-like-illness LSTM long short-term memory MSE mean squared error 1 Introduction Influenza-like illness (ILI) is a major contributor to morbidity and mortality each year and represents an ongoing challenge to public health policy and infrastructure [1]. With the recent coronavirus disease 19 (COVID-19) pandemic, the burden and influence of the flu has become more complex.

Abstract Visceral pain (VP) is a global problem with complex etiologies and limited therapeutic options. Guanylyl cyclase C (GUCY2C), an intestinal receptor producing cyclic GMP(cGMP), which regulates luminal fluid secretion, has emerged as a therapeutic target for VP. Indeed, FDA-approved GUCY2C agonists ameliorate VP in patients with chronic constipation syndromes, although analgesic mechanisms remain obscure.

Abstract Visceral pain associated with irritable bowel syndrome afflicts 15% of the US population. Although treatments are limited, guanylyl cyclase C (GUCY2C) agonists alleviate pain and constipation. Until now, it was assumed that the activation of GUCY2C and production of cGMP in enterocytes stimulated fluid secretion and reduced visceral sensation.